Extension of the Cancer Immunotherapy Pilot Program and Request for Comments
保存版の掲載情報です。最新の営業状況・料金・利用条件は出典をご確認ください。
保存されている情報
On June 29, 2016, the United States Patent and Trademark Office (USPTO) implemented the Cancer Immunotherapy Pilot Program in support of the White House's National Cancer Moonshot initiative, which sought to accelerate cancer research. The program permits patent applications pertaining to cancer immunotherapy to be advanced out of turn for examination. To date, over 835 petitions requesting participation in the pilot program have been filed, and over 615 patents have been granted under the program. In view of the continued interest in the Cancer Immunotherapy Pilot Program, as well as the White House's recent reignition of the National Cancer Moonshot initiative, the USPTO is extending the program, with all parameters remaining the same, until September 30, 2022. The USPTO is also in the process of deciding whether to expand the scope of the pilot program and may, additionally, further extend it (with or without modifications), depending on feedback from the participants and the public, additional continued interest, and the program's effectiveness.
- Current entry point
- www.federalregister.gov/documents/2022/06/29/2022-13908/extension-of-the-cancer-immunotherapy-pilot-program-and-request-for-comments (permanent link in the Federal Register, verified 2026-09-30)
- Legacy system and where it moved
- No legacy system name mention in title or summary )
- Fee
- Fee mentioned in title or summary (Confirmed in the document text)
- What you need (account or API key)
- No account or key mention in title or summary )
- Published
- 2022-06-29
- Document type
- Notice
原データ更新日：2026-10-06
保存版に記録された日付です。今回の実装・デプロイ日ではありません。